The ENDORSE-HF trial showed that adding the SGLT2 inhibitor dapagliflozin to diuretic therapy in acute heart failure patients results in rapid decongestion, shorter hospital stays, increased natriuresis, and improved ejection fraction. This combination also allows for the early introduction of key heart failure therapies. The study demonstrated that the initiation of SGLT2 inhibitors during acute congestion is safe and improves outcomes. This new approach challenges the traditional mindset around heart failure management and shows promising results for patients with acute heart failure. The findings provide a strong rationale for incorporating SGLT2 inhibitors into treatment protocols for heart failure patients.
Source link
SGLT2s With Diuretics Improve Heart Failure Outcomes
